MedTrace Logo

Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial

NCT01638416 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4994

Last updated 2020-10-22

Study results available
· View outcomes & findings →

Summary

In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. During the last decade, it has been reported that blood transfusion in patients admitted to intensive care was associated with an independent increase of mortality. Some research suggests that transfusion of fresher blood might help patients in the intensive care unit to reach a better recovery. This project will test whether patients who receive 'fresher' blood do better than patients who receive 'standard issue' blood.

Conditions

  • Transfusion
  • Age of Blood

Interventions

OTHER

Blood transfusion

Blood transfusion in ICU patients aged 18 and over.

Sponsors & Collaborators

  • Australian Red Cross

    collaborator OTHER

  • New Zealand Blood Service

    collaborator OTHER

  • Irish Blood Transfusion Service

    collaborator OTHER

  • Finnish Red Cross Blood Service

    collaborator OTHER

  • King Abdulaziz Medical City

    collaborator OTHER_GOV

  • University College Dublin

    collaborator OTHER

  • Australian and New Zealand Intensive Care Research Centre

    lead OTHER

Principal Investigators

  • D. James Cooper, A.O., M.D. · Monash University/Alfred Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2017-04-30
Completion
2017-06-30

Countries

  • Australia
  • Finland
  • Ireland
  • New Zealand
  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01638416 on ClinicalTrials.gov